RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer - Nature

Scientists caution that more research is needed, but nearly all of the patients who responded to the personalized vaccine are still alive six years later.

Big Muddy is Jean-Paul R. Soucy's blog about technology, science, politics, and other curiosities.

Big Muddy is Jean-Paul R. Soucy's blog about technology, science, politics, and other curiosities.

Apart from looking like he has just been on the losing end of a fistfight, and having occasional bouts of nausea, Ben Sasse seems to be doing as well as someone recently diagnosed with metastatic pancreatic cancer possibly could. Both the nausea and his face peeling off are because of daraxonrasib, a new drug which targets KRAS G12 mutations which are common in many cancers but are found in most pancreatic ductal adenocarcinoma (PDAC). As a reminder, PDAC is the one that Steve Jobs did not have, the one that has the dubious distinction of being both the most common and the most lethal cancer of the pancreas.

Cancer therapies based on mRNA vaccine technology have been among the most promising medical developments of the past decade. That promise is now beginning to …

Scientists caution that more research is needed, but nearly all of the patients who responded to the personalized vaccine are still alive six years later.